This Phase I/II study is designed to first identify doses of MLN9708 and bendamustine that are associated with an acceptable adverse event profile when delivered together in 28-day cycles. Additionally, the study aims to assess the efficacy of the combination in patients with relapsed/refractory multiple myeloma. Responders (stable disease or more), will continue to receive up to 8 cycles total in the absence of further progressive disease.
SparkCures ID | 741 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 26 Patients |
Treatments |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
INCLUSION CRITERIA:
EXCLUSION CRITERIA
Please visit the ClinicalTrials.gov page for historical site information.
View Centers